A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction

Ki Hak Moon, Sae Woong Kim, Du Geon Moon, Je-Jong Kim, Nam Cheol Park, Sung Won Lee, Jae Seung Paick, Tai Young Ahn, Woo Sik Chung, Kwon Sik Min, Jong Kwan Park, Dae Yul Yang, Hong Seok Shin, Kwangsung Park

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction Once-daily administration of phosphodiesterase type 5 inhibitors has been shown to correct erectile dysfunction (ED). Aim To evaluate the long-term efficacy and safety after once-daily oral administration of udenafil 75 mg in men with ED. Methods This clinical trial was an open-label, fixed-dose, 24-week extension study (DA8159_EDDL_III) of a 24-week double-blinded efficacy and safety study of once-daily udenafil (parent study: DA8159_EDD_III). Subjects received udenafil 75 mg once daily for 24 weeks during this extension study, and the follow-up visit occurred during the 4-week ED treatment-free period. Main Outcome Measures Subjects were asked to complete the International Index of Erectile Function questionnaire and the Global Assessment Questionnaire at the 24-week extension and after the 4-week ED treatment-free period, and the development of adverse drug reactions was investigated. Results In total, 302 subjects were enrolled in this extension study. Improvement was shown with an increased erectile function (EF) domain score compared with baseline (14.60 ± 4.57) at extension week 48 (23.98 ± 5.44) and a slight increase in EF domain score compared with the last time point (week 24) of the parent study (P < .001). The Global Assessment Questionnaire showed a high improvement rate of 95.4% at the extension 48-week time point. For shift to normal, almost half the subjects (45.1%) recovered “normal” EF, and 14.2% of subjects reported normal erections after the 4-week ED treatment-free period. The occurrence rate of adverse drug reactions was 8%, which consisted mainly of flushing and headache. Conclusion Once-daily dosing of udenafil 75 mg showed excellent efficacy and safety with long-term administration and allowed a more spontaneous sexual life.

Original languageEnglish
Pages (from-to)1263-1269
Number of pages7
JournalJournal of Sexual Medicine
Volume13
Issue number8
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

udenafil
Erectile Dysfunction
Safety
Drug-Related Side Effects and Adverse Reactions
Phosphodiesterase 5 Inhibitors
Headache
Oral Administration
Therapeutics
Outcome Assessment (Health Care)
Clinical Trials

Keywords

  • Erectile Dysfunction
  • Long Term
  • Phosphodiesterase Type 5 Inhibitors
  • Udenafil

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology
  • Urology

Cite this

A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction. / Moon, Ki Hak; Kim, Sae Woong; Moon, Du Geon; Kim, Je-Jong; Park, Nam Cheol; Lee, Sung Won; Paick, Jae Seung; Ahn, Tai Young; Chung, Woo Sik; Min, Kwon Sik; Park, Jong Kwan; Yang, Dae Yul; Shin, Hong Seok; Park, Kwangsung.

In: Journal of Sexual Medicine, Vol. 13, No. 8, 01.01.2016, p. 1263-1269.

Research output: Contribution to journalArticle

Moon, KH, Kim, SW, Moon, DG, Kim, J-J, Park, NC, Lee, SW, Paick, JS, Ahn, TY, Chung, WS, Min, KS, Park, JK, Yang, DY, Shin, HS & Park, K 2016, 'A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction', Journal of Sexual Medicine, vol. 13, no. 8, pp. 1263-1269. https://doi.org/10.1016/j.jsxm.2016.05.011
Moon, Ki Hak ; Kim, Sae Woong ; Moon, Du Geon ; Kim, Je-Jong ; Park, Nam Cheol ; Lee, Sung Won ; Paick, Jae Seung ; Ahn, Tai Young ; Chung, Woo Sik ; Min, Kwon Sik ; Park, Jong Kwan ; Yang, Dae Yul ; Shin, Hong Seok ; Park, Kwangsung. / A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction. In: Journal of Sexual Medicine. 2016 ; Vol. 13, No. 8. pp. 1263-1269.
@article{67ccadead23d4ce795eaaae4d9956675,
title = "A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction",
abstract = "Introduction Once-daily administration of phosphodiesterase type 5 inhibitors has been shown to correct erectile dysfunction (ED). Aim To evaluate the long-term efficacy and safety after once-daily oral administration of udenafil 75 mg in men with ED. Methods This clinical trial was an open-label, fixed-dose, 24-week extension study (DA8159_EDDL_III) of a 24-week double-blinded efficacy and safety study of once-daily udenafil (parent study: DA8159_EDD_III). Subjects received udenafil 75 mg once daily for 24 weeks during this extension study, and the follow-up visit occurred during the 4-week ED treatment-free period. Main Outcome Measures Subjects were asked to complete the International Index of Erectile Function questionnaire and the Global Assessment Questionnaire at the 24-week extension and after the 4-week ED treatment-free period, and the development of adverse drug reactions was investigated. Results In total, 302 subjects were enrolled in this extension study. Improvement was shown with an increased erectile function (EF) domain score compared with baseline (14.60 ± 4.57) at extension week 48 (23.98 ± 5.44) and a slight increase in EF domain score compared with the last time point (week 24) of the parent study (P < .001). The Global Assessment Questionnaire showed a high improvement rate of 95.4{\%} at the extension 48-week time point. For shift to normal, almost half the subjects (45.1{\%}) recovered “normal” EF, and 14.2{\%} of subjects reported normal erections after the 4-week ED treatment-free period. The occurrence rate of adverse drug reactions was 8{\%}, which consisted mainly of flushing and headache. Conclusion Once-daily dosing of udenafil 75 mg showed excellent efficacy and safety with long-term administration and allowed a more spontaneous sexual life.",
keywords = "Erectile Dysfunction, Long Term, Phosphodiesterase Type 5 Inhibitors, Udenafil",
author = "Moon, {Ki Hak} and Kim, {Sae Woong} and Moon, {Du Geon} and Je-Jong Kim and Park, {Nam Cheol} and Lee, {Sung Won} and Paick, {Jae Seung} and Ahn, {Tai Young} and Chung, {Woo Sik} and Min, {Kwon Sik} and Park, {Jong Kwan} and Yang, {Dae Yul} and Shin, {Hong Seok} and Kwangsung Park",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.jsxm.2016.05.011",
language = "English",
volume = "13",
pages = "1263--1269",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction

AU - Moon, Ki Hak

AU - Kim, Sae Woong

AU - Moon, Du Geon

AU - Kim, Je-Jong

AU - Park, Nam Cheol

AU - Lee, Sung Won

AU - Paick, Jae Seung

AU - Ahn, Tai Young

AU - Chung, Woo Sik

AU - Min, Kwon Sik

AU - Park, Jong Kwan

AU - Yang, Dae Yul

AU - Shin, Hong Seok

AU - Park, Kwangsung

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction Once-daily administration of phosphodiesterase type 5 inhibitors has been shown to correct erectile dysfunction (ED). Aim To evaluate the long-term efficacy and safety after once-daily oral administration of udenafil 75 mg in men with ED. Methods This clinical trial was an open-label, fixed-dose, 24-week extension study (DA8159_EDDL_III) of a 24-week double-blinded efficacy and safety study of once-daily udenafil (parent study: DA8159_EDD_III). Subjects received udenafil 75 mg once daily for 24 weeks during this extension study, and the follow-up visit occurred during the 4-week ED treatment-free period. Main Outcome Measures Subjects were asked to complete the International Index of Erectile Function questionnaire and the Global Assessment Questionnaire at the 24-week extension and after the 4-week ED treatment-free period, and the development of adverse drug reactions was investigated. Results In total, 302 subjects were enrolled in this extension study. Improvement was shown with an increased erectile function (EF) domain score compared with baseline (14.60 ± 4.57) at extension week 48 (23.98 ± 5.44) and a slight increase in EF domain score compared with the last time point (week 24) of the parent study (P < .001). The Global Assessment Questionnaire showed a high improvement rate of 95.4% at the extension 48-week time point. For shift to normal, almost half the subjects (45.1%) recovered “normal” EF, and 14.2% of subjects reported normal erections after the 4-week ED treatment-free period. The occurrence rate of adverse drug reactions was 8%, which consisted mainly of flushing and headache. Conclusion Once-daily dosing of udenafil 75 mg showed excellent efficacy and safety with long-term administration and allowed a more spontaneous sexual life.

AB - Introduction Once-daily administration of phosphodiesterase type 5 inhibitors has been shown to correct erectile dysfunction (ED). Aim To evaluate the long-term efficacy and safety after once-daily oral administration of udenafil 75 mg in men with ED. Methods This clinical trial was an open-label, fixed-dose, 24-week extension study (DA8159_EDDL_III) of a 24-week double-blinded efficacy and safety study of once-daily udenafil (parent study: DA8159_EDD_III). Subjects received udenafil 75 mg once daily for 24 weeks during this extension study, and the follow-up visit occurred during the 4-week ED treatment-free period. Main Outcome Measures Subjects were asked to complete the International Index of Erectile Function questionnaire and the Global Assessment Questionnaire at the 24-week extension and after the 4-week ED treatment-free period, and the development of adverse drug reactions was investigated. Results In total, 302 subjects were enrolled in this extension study. Improvement was shown with an increased erectile function (EF) domain score compared with baseline (14.60 ± 4.57) at extension week 48 (23.98 ± 5.44) and a slight increase in EF domain score compared with the last time point (week 24) of the parent study (P < .001). The Global Assessment Questionnaire showed a high improvement rate of 95.4% at the extension 48-week time point. For shift to normal, almost half the subjects (45.1%) recovered “normal” EF, and 14.2% of subjects reported normal erections after the 4-week ED treatment-free period. The occurrence rate of adverse drug reactions was 8%, which consisted mainly of flushing and headache. Conclusion Once-daily dosing of udenafil 75 mg showed excellent efficacy and safety with long-term administration and allowed a more spontaneous sexual life.

KW - Erectile Dysfunction

KW - Long Term

KW - Phosphodiesterase Type 5 Inhibitors

KW - Udenafil

UR - http://www.scopus.com/inward/record.url?scp=84994793920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994793920&partnerID=8YFLogxK

U2 - 10.1016/j.jsxm.2016.05.011

DO - 10.1016/j.jsxm.2016.05.011

M3 - Article

VL - 13

SP - 1263

EP - 1269

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 8

ER -